Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

15.18
+0.61004.19%
Post-market: 15.180.00000.00%16:10 EST
Volume:35.02K
Turnover:526.90K
Market Cap:2.65B
PE:5.73
High:15.30
Open:14.75
Low:14.75
Close:14.57
52wk High:19.50
52wk Low:11.51
Shares:174.43M
Float Shares:104.00M
Volume Ratio:1.10
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.65
EPS(LYR):0.2000
ROE:46.90%
ROA:-0.81%
PB:2.15
PE(LYR):75.90

Loading ...

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

GlobeNewswire
·
Yesterday

Lexicon Announces Proposed Public Offering of Common Stock

GlobeNewswire
·
Jan 30

BOCOM International Holdings Company Sticks to Their Buy Rating for HUTCHMED (China) (HCM)

TIPRANKS
·
Jan 29

Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM

TIPRANKS
·
Jan 27

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

GlobeNewswire
·
Jan 27

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

GlobeNewswire
·
Jan 27

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

GlobeNewswire
·
Jan 23

Humanforce Strengthens Executive Team with Appointment of Cameron Partridge as Chief Growth Officer

prnewswire
·
Jan 20

Hutchmed (00013) Rises Over 4% Again, Up More Than 20% This Month; SACHI Phase III Study Results Published in The Lancet

Stock News
·
Jan 16

HUTCHMED Surges Over 3% in Intraday Trading as SACHI Phase III Study Results Published in The Lancet

Deep News
·
Jan 15

Hutchmed reports publication of SACHI results in The Lancet

TIPRANKS
·
Jan 14

HUTCHMED (00013) Announces Publication of SACHI Phase III Study Results in The Lancet

Stock News
·
Jan 14

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

GlobeNewswire
·
Jan 09

Multiple Positive Catalysts Drive Five-Day Rally, Is HUTCHMED (00013) Turning Around After Missing the Bull Run?

Stock News
·
Jan 09

Hutchmed Says Autoimmune Disorder Trial in China Meets Primary Endpoint

MT Newswires Live
·
Jan 07

HUTCHMED (00013) Announces Positive Top-Line Results from Phase III Stage of ESLIM-02 Study of Sovleplenib in Warm Antibody Autoimmune Hemolytic Anemia in China

Stock News
·
Jan 07

A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update

Simply Wall St.
·
Jan 07

Malaysian Shares Rebound Mirroring Regional Gains; Vetece's Shares Rise 4%

MT Newswires Live
·
Jan 05

Hutchmed Starts Phase III Trial of Pancreatic Cancer Treatment Combination

MT Newswires Live
·
Jan 05

Vetece Unit Wins About MYR13 Million HCM Cloud Deal

MT Newswires Live
·
Jan 05